Myriad reiterates $860M-$880M 2026 revenue outlook while advancing Precise MRD and FirstGene launches
Myriad Genetics Inc · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · Now $4.28
-13% in 7d after detection
Post-detection moves
1h
—
1d
-0.5%
3d
+2.4%
7d
-13%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS